WO2017208665A1 - Fibre d'agglutination de cellules sanguines - Google Patents

Fibre d'agglutination de cellules sanguines Download PDF

Info

Publication number
WO2017208665A1
WO2017208665A1 PCT/JP2017/015969 JP2017015969W WO2017208665A1 WO 2017208665 A1 WO2017208665 A1 WO 2017208665A1 JP 2017015969 W JP2017015969 W JP 2017015969W WO 2017208665 A1 WO2017208665 A1 WO 2017208665A1
Authority
WO
WIPO (PCT)
Prior art keywords
fiber
hemagglutinating
molecular weight
cationic polymer
agent
Prior art date
Application number
PCT/JP2017/015969
Other languages
English (en)
Japanese (ja)
Inventor
佑佳 鈴木
繁宏 松原
雅史 小栗
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201780033387.2A priority Critical patent/CN109196160A/zh
Publication of WO2017208665A1 publication Critical patent/WO2017208665A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
    • D06M15/21—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • the present invention relates to a fiber having an erythrocyte aggregation action.
  • Patent Document 1 describes a method for producing an antibacterial substance in which a cellulose material such as cotton or wood pulp and an antibacterial cationic polyelectrolyte are mixed to form a non-leaching bond between them. Yes.
  • This antibacterial substance is used for sanitary napkins and tampons.
  • polydiallyldimethylammonium chloride is used as the antibacterial cationic polyelectrolyte.
  • the present invention provides a hemagglutinating fiber in which a hemagglutinating agent is contained inside the fiber.
  • the present invention also provides a cationic polymer-containing fiber in which a cationic polymer is contained inside the fiber.
  • FIG. 1 is a plan view showing an embodiment of an absorbent article including the hemagglutinating fiber of the present invention.
  • FIG.2 (a) and FIG.2 (b) are the schematic diagrams which show the absorption mechanism of the menstrual blood in the conventional absorbent article.
  • FIG. 3 is a schematic diagram showing a menstrual blood absorption mechanism in an absorbent article including the hemagglutinating fiber of the present invention.
  • a non-leaching bond is formed between the cationic polyelectrolyte and the cellulose material in order to maintain the antibacterial effect. If a non-leaching bond is formed between the cationic polyelectrolyte and the cellulosic material, the cationic polyelectrolyte cannot leach and act on the red blood cells, so it can exhibit antibacterial properties. However, it is insufficient to agglutinate red blood cells. In order to agglutinate erythrocytes more stably, it is necessary to take a behavior that the cationic polyelectrolyte is leached continuously.
  • the present invention relates to improvement of a material for treating menstrual blood, and more particularly, to a fiber that maintains the effect of treating menstrual blood even after repeatedly contacting with menstrual blood and an article including the same.
  • the hemagglutinating fiber of the present invention has an action of agglutinating red blood cells in blood by elution of the hemagglutinating agent contained in the fiber by contact with blood.
  • the blood mentioned here is generally human blood, but is not limited thereto.
  • the hemagglutinating fiber is obtained by applying a hemagglutinating agent to the fiber.
  • a representative example of the hemagglutinating agent is a cationic polymer
  • the cationic polymer-containing fiber is obtained by applying a cationic polymer to a fiber.
  • the cationic polymer-containing fiber also has the same configuration and action as the hemagglutinating fiber.
  • the fiber used for the hemagglutinating fiber of the present invention has an elongated shape having a length that is large relative to its thickness. Thickness is the diameter of a circle when the cross section of the fiber is a circle, and when the cross section is a shape other than a circle, the longest side is the longest side of the line segment that crosses the cross section of the fiber. And the long side when the shortest side is short.
  • the fiber thickness is not constant along the length direction as in the case of pulp fibers, the fiber thickness means the longest line segment across the cross section of the fiber in the length direction.
  • the length of the fiber is generally at least 5 times the thickness, and there is no limit on the upper limit.
  • the thickness of the fiber used for the hemagglutinating fiber of the present invention can be appropriately selected depending on the specific use of the hemagglutinating fiber.
  • the thickness of the fiber is 0 from the viewpoint of providing a strength that can be formed as a fiber sheet and can be endured as an absorbent article. It is preferably 1 ⁇ m or more, more preferably 1 ⁇ m or more, and even more preferably 10 ⁇ m or more.
  • the thickness of the fiber is preferably from 0.1 ⁇ m to 1000 ⁇ m, more preferably from 1 ⁇ m to 500 ⁇ m, and even more preferably from 10 ⁇ m to 200 ⁇ m.
  • the thickness of the hemagglutinating fiber and the thickness of the fiber constituting the hemagglutinable fiber can be substantially identical. Therefore, the thickness of the hemagglutinating fiber is preferably in the range as described above.
  • the thickness of the hemagglutinating fiber and the thickness of the fiber constituting the hemagglutinating fiber are measured by magnifying observation with a scanning electron microscope.
  • the length in which the line segment along the direction orthogonal to the longitudinal direction of the fiber crosses the fiber is defined as the fiber thickness.
  • the measurement is performed at 10 or more positions in the same or different fibers, and the calculated average value is defined as the fiber thickness, that is, the fiber diameter.
  • the hemagglutinating fiber of the present invention is characterized by the presence of a hemagglutinating agent applied to the fiber. Specifically, the hemagglutinating agent is contained at least inside the fiber.
  • the inside of the fiber is a region inside the contour line in a two-dimensional shape (hereinafter also referred to as “cross-sectional shape”) when the fiber is viewed in cross section.
  • the hemagglutinating agent may be present in the entire region inside the contour line in the cross-sectional shape, or the region where the hemagglutinating agent is present and the non-existing region are present in the region inside the contour line in the cross-sectional shape. It may exist to be formed.
  • the hemagglutinating agent When the hemagglutinating agent is present in the entire region inside the contour line in the cross-sectional shape, the hemagglutinating agent may be uniformly present in the region inside the contour line in the cross-sectional shape, Or you may exist with distribution. When the hemagglutinating agent is present with a distribution, the hemagglutinating agent may be present in the central region relatively more than the peripheral region in the cross-sectional shape, or may be relatively present in the peripheral region rather than the central region. Many may exist.
  • the hemagglutinating agent only needs to be contained in at least the inside of the fiber, and it is not hindered that the hemagglutinating agent is additionally present on the surface of the fiber.
  • the hemagglutinating agent contained at least inside the fiber has the following advantages. That is, when the hemagglutinating fiber comes into contact with blood, the hemagglutinating agent contained in the hemagglutinating fiber is eluted, and the hemagglutinating agent aggregates erythrocytes in the blood. In this case, if the hemagglutinating agent is present only on the surface of the fiber, the hemagglutinating agent tends to be washed away in the blood due to contact between the hemagglutinating agent and blood, and the hemagglutinating agent on the fiber surface The abundance of will decrease early.
  • the hemagglutinating agent is contained in at least the inside of the fiber, the rate of elution of the hemagglutinating agent from the inside of the hemagglutinating fiber toward the surface can be controlled, so the number of contact with blood increases.
  • the hemagglutination action continues even if it is taken. That is, the hemagglutinating fiber of the present invention has a sustained release property for the hemagglutinating agent. Therefore, the hemagglutinating agent of the present invention has a blood cell aggregating action that lasts for a long time.
  • the presence distribution of the hemagglutinating agent in the cross-sectional shape of the fiber can be quantitatively displayed on the basis of the permeability.
  • Penetration rate is the S / N ratio (signal) measured for the elements constituting the hemagglutinating agent using a scanning electron microscope-energy dispersive X-ray fluorescence spectrometer (SEM-EDX) for the cross section of the fiber. / Noise ratio).
  • SEM-EDX scanning electron microscope-energy dispersive X-ray fluorescence spectrometer
  • the S / N ratio is measured for an element different from the element constituting the fiber among the elements constituting the hemagglutinating agent.
  • An example of such an element is chlorine (Cl).
  • Identification of elements constituting the hemagglutinating agent can be performed, for example, as follows. First, with respect to a commercially available absorbent article such as a napkin, the hot melt bonding each member is nullified using a dryer or the like, and decomposed into members such as a top sheet, an absorbent body, and a back sheet. A multistage solvent extraction method from a nonpolar solvent to a polar solvent is performed on each decomposed member to separate the hemagglutinating agent used in each member to obtain a solution containing a single compound.
  • the S / N ratio using SEM-EDX is measured by measuring the peak intensity of the hemagglutinating agent element different from the element constituting the fiber identified by the above-mentioned method by adjusting the electron beam with the cross section of the fiber as the measurement object. .
  • the ratio of the obtained peak intensity of S (signal) and peak intensity of N (noise) is calculated.
  • the calculated ratio, that is, the S / N ratio is defined as the permeability.
  • the irradiation position of the electron beam in the cross section of the fiber is in a range corresponding to a square in which the length of one side from the center of the cross section of the fiber is about half or less of the short side in the fiber cross section.
  • the signal obtained at the site other than the irradiation position of the beam is more than the signal obtained above. It is preferable that the signal obtained at the irradiation position of the beam is larger.
  • the fiber used for the hemagglutinating fiber either natural fiber or synthetic fiber may be used.
  • natural fibers include plant-derived cellulose fibers and rayon fibers.
  • synthetic fiber the fiber which consists of a thermoplastic resin which has fiber formation ability, for example is mentioned.
  • thermoplastic resin having fiber forming ability include various polyolefin fibers such as polyethylene and polypropylene, various polyester fibers such as polyethylene terephthalate and polybutylene terephthalate, and various acrylic fibers such as polyacrylic acid and polymethyl methacrylate.
  • various vinyl fibers such as polystyrene and polyvinyl chloride. These fibers can be used alone or in combination of two or more. Of these fibers, it is preferable to use cellulose fibers because the hemagglutinating agent easily penetrates into the fibers.
  • Beating is an operation in which cellulose fibers such as pulp are mechanically beaten and ground in the presence of water.
  • the degree of beating of cellulose fibers can be quantitatively expressed by the beating degree (also called the freeness).
  • the degree of beating of the cellulose fiber expressed by the beating degree is preferably 780 mL or less, more preferably 600 mL or less, and more preferably 400 mL or less from the viewpoint that the hemagglutinating agent easily penetrates into the fiber. Is more preferable.
  • the lower limit of the beating degree is preferably 100 mL or more, more preferably 200 mL or more, and further preferably 300 mL or more from the viewpoint of maintaining the fiber length and maintaining the workability.
  • the beating degree is preferably 100 mL or more and 780 mL or less, more preferably 200 mL or more and 600 mL or less, and further preferably 300 mL or more and 400 mL or less.
  • the preferred beating degree value of the hemagglutinating fiber is within the above range.
  • the freeness measured using the same method is defined as the beating degree.
  • hemagglutinating agent used in the hemagglutinating fiber of the present invention those having an action capable of aggregating erythrocytes in blood are used.
  • the “hemagglutinating agent” has an action of aggregating red blood cells in blood, and acts to separate the aggregated aggregate and plasma components. Red blood cells aggregated by the hemagglutinating agent become aggregates.
  • a strongly positively charged linear cationic polymer such as acrylamide copolymer or polylysine can be used.
  • a triblock copolymer of polypropylene oxide and polyethylene oxide can be used.
  • An example of such a triblock copolymer is “Pluronic F-98” available from BASF.
  • a hemagglutinating agent what is described in international publication 2016/093233 can be used arbitrarily.
  • a cationic polymer is useful as a hemagglutinating agent.
  • the reason is as follows.
  • Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • sialic acid a sugar having an anionic charge
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles
  • a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain
  • the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.
  • the hemagglutinating agent cationic polymer
  • the hemagglutinating agent used in the present invention has the property that, when 1000 ppm of a measurement sample is added to simulated blood, at least two or more red blood cells aggregate to form an aggregate in a state in which the blood fluidity is maintained. It is what has.
  • the above-mentioned “state in which the fluidity of blood is maintained” means that 10 g of simulated blood to which a measurement sample agent is added 1000 ppm is screw tube bottle (manufactured by Maruemu Co., Ltd., product number “screw tube No. 4”, mouth inner diameter 14.5 mm, When the screw tube bottle containing the simulated blood is turned 180 degrees, it is in a state where 80% or more of the simulated blood flows down within 5 seconds.
  • Simulated blood means that the viscosity measured with a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement conditions: rotor No. 19, 30 rpm, 60 seconds) is 8 mPa ⁇ s at 25 ° C.
  • the blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories) is adjusted.
  • Whether or not “two or more erythrocytes have aggregated to form an aggregate” is determined as follows. That is, simulated blood to which a measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (manufactured by Horiba, Ltd., model number: LA-950V2, measurement condition: flow type). The median diameter of volume average particle size measured at a temperature of 25 ° C. by a laser diffraction scattering method using cell measurement, circulation speed 1, no ultrasonic wave) corresponds to the size of an aggregate obtained by aggregating two or more red blood cells. If it is 10 ⁇ m or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.
  • the hemagglutinating agent used in the present invention satisfies the above-mentioned properties by a single compound that meets the above-mentioned properties, a mixture of a plurality of single compounds that meet the above-mentioned properties, or a combination of a plurality of compounds.
  • Agent capable of expressing aggregation That is, the hemagglutinating agent is an agent limited to those having a hemagglutinating action as defined above. Therefore, when the hemagglutinating agent contains a third component that does not meet the above definition, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.
  • the “single compound” is a concept including compounds having the same composition formula but having different molecular weights due to different numbers of repeating units.
  • the hemagglutinating agent used in the present invention those containing a cationic polymer are preferable.
  • the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride.
  • the hemagglutinating agent used in the present invention can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer.
  • the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization.
  • the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things.
  • the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.
  • the hemagglutinating agent used in the present invention contains a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer
  • the hemagglutination The agent may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. May be included.
  • a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types.
  • the quaternary ammonium salt copolymer can be used alone or in combination of two or more.
  • a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.
  • quaternary ammonium salt polymer a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate from the viewpoint of adsorptivity to erythrocytes. preferable.
  • the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as “quaternary ammonium salt polymer”.
  • the quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.
  • the quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety.
  • a quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent.
  • the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce
  • the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and diethyl sulfate.
  • dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur.
  • the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. .
  • a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized.
  • Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.
  • the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more.
  • the upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less.
  • the molecular weight of the cationic polymer is preferably 2000 or more and 10 million or less, more preferably 2000 or more and 5 million or less, still more preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferably 30,000 to 3,000,000.
  • the molecular weight referred to in the present invention is a weight average molecular weight.
  • the molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions.
  • the molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.
  • a column in which a guard column ⁇ manufactured by Tosoh Corporation and an analytical column ⁇ -M are connected in series is used at a column temperature of 40 ° C.
  • the detector uses RI (refractive index).
  • 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 ⁇ L.
  • Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 ⁇ L.
  • the cationic polymer is also preferably a mixture of two or more cationic polymers having different weight average molecular weights. This further improves the blood cell aggregation effect. Specifically, a relatively low molecular weight cationic polymer plays a role in neutralizing the blood cell surface charge, while a relatively high molecular weight cationic polymer plays a role in forming blood cell aggregates. To do. From this viewpoint, when the cationic polymer is a mixture of two kinds of cationic polymers having different weight average molecular weights, the relatively low molecular weight cationic polymer preferably has a weight average molecular weight of 2000 or more.
  • the relatively high molecular weight cationic polymer is preferably 150,000 or more, provided that its weight average molecular weight is higher than that of the relatively low molecular weight cationic polymer.
  • the cationic polymer is a mixture of two or more kinds of cationic polymers having different weight average molecular weights, for example, a mixture of a cationic polymer A having a relatively low molecular weight and a cationic polymer B having a relatively high molecular weight.
  • the cationic polymer A and the cationic polymer B may be the same type of polymers having different weight average molecular weights, or may be polymers having different weight average molecular weights and different types.
  • the cationic polymer is a mixture of two or more kinds of cationic polymers having different weight average molecular weights
  • the molecular weight distribution has two peaks. This further improves the sustained release properties of the hemagglutinating agent.
  • the relatively low molecular weight cationic polymer elutes early in contact with blood, while the relatively high molecular weight cationic polymer elutes later in contact with blood.
  • the difference in peak of the molecular weight distribution is preferably 300,000 or more, and more preferably 500,000 or more.
  • the difference in peak of the molecular weight distribution is preferably from 300,000 to 3,000,000, more preferably from 500,000 to 2,000,000, and even more preferably from 700,000 to 1,000,000.
  • the difference in the peak of the molecular weight distribution is the difference between the weight average molecular weight of the relatively high molecular weight cationic polymer and the weight average molecular weight of the relatively low molecular weight cationic polymer.
  • the cationic polymer is a mixture of two or more kinds of cationic polymers having different weight average molecular weights, for example, a mixture of a cationic polymer A having a relatively low molecular weight and a cationic polymer B having a relatively high molecular weight.
  • the cationic polymer A and the cationic polymer B may be the same type of polymers having different weight average molecular weights, or may be polymers having different weight average molecular weights and different types.
  • the cationic polymer is preferably water-soluble.
  • water-soluble means that 0.05 g of 1 mm or less powdery or 0.5 mm or less film-form cationic polymer is added to and mixed with 50 mL of deionized water at 25 ° C. in a 100 mL glass beaker (5 mm ⁇ ).
  • a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd.
  • the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
  • the cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium moiety is preferably present in the side chain.
  • the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs.
  • bonded at one point means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain.
  • Connected at two or more points means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain.
  • a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto.
  • the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more.
  • the upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less.
  • the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less.
  • the carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included.
  • the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the aforementioned range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of red blood cells is reduced.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer
  • examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety.
  • a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization are examples of the homopolymer.
  • alkylating agent and the acid are as described above.
  • the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.
  • quaternary ammonium salt homopolymer examples include polyethyleneimine.
  • examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer
  • two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer.
  • a copolymer obtained by the above copolymerization can be used.
  • a quaternary ammonium salt copolymer one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety
  • the copolymer obtained by copolymerizing using 1 or more types of bodies can be used.
  • the quaternary ammonium salt copolymer can be a binary copolymer or a ternary or higher copolymer.
  • the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer
  • charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated.
  • Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine.
  • Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds.
  • nonionic polymerizable monomers examples include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate.
  • One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do.
  • a quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).
  • a polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety.
  • a polymerizable monomer having no quaternary ammonium moiety When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed.
  • the functional group capable of hydrogen bonding include —OH, —NH 2 , —CHO, —COOH, —HF, —SH and the like.
  • polymerizable monomers having functional groups capable of hydrogen bonding examples include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl An acrylate etc. are mentioned.
  • hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used.
  • a polymerizable monomer for copolymerization By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced.
  • functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups.
  • polymerizable monomers having functional groups capable of hydrophobic interaction examples include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned.
  • methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate
  • a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used as the polycondensate.
  • Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.
  • the quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer described above can be obtained by a homopolymerization method or a copolymerization method of a vinyl polymerizable monomer.
  • the polymerization method for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.
  • the flow potential of the quaternary ammonium salt polymer is preferably 1500 ⁇ eq / L or more, more preferably 2000 ⁇ eq / L or more, more preferably 3000 ⁇ eq / L, from the viewpoint of more effectively generating red blood cell aggregates. L or more is more preferable, and 4000 ⁇ eq / L or more is even more preferable.
  • the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized.
  • the upper limit of the streaming potential is preferably 13000 ⁇ eq / L or less, more preferably 8000 ⁇ eq / L or less, and even more preferably 6000 ⁇ eq / L or less.
  • the flow potential of the quaternary ammonium salt polymer can be adjusted, for example, by adjusting the molecular weight of the constituting cationic monomer itself, or by coordinating the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. It can be controlled by adjusting the polymerization molar ratio.
  • the streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, with respect to a commercially available napkin, the hot melt which adhere
  • a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition.
  • the obtained solution was dried and solidified, and 1 H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC ( Gel permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent.
  • inorganic value / organic value hereinafter referred to as “IOB (Inorganic Organic Balance) value
  • the properties of a substance are largely controlled by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Wals force due to molecular mass and electric affinity due to the polarity of the molecule. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electrical affinity can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to.
  • This idea is a theory well known as “organic conceptual diagram”.
  • Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic.
  • the degree of physical properties due to Van Der Waals force is called ⁇ organic ''
  • the degree of physical properties mainly due to electrical affinity is called ⁇ inorganic ''
  • the physical properties of substances are considered as a combination of “organic” and “inorganic”.
  • one carbon (C) is defined as organic 20
  • the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value.
  • the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values
  • the IOB value of the cationic polymer is determined based on the value.
  • the sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.
  • the IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate.
  • the sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.
  • the IOB value of a cationic polymer such as a quaternary ammonium salt polymer is preferably 0.6 or more, more preferably 1.8 or more, still more preferably 2.1 or more, More preferably, it is 2.2 or more. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3 or less. The IOB value is more preferably 1.8 or more and 3.6 or less, further preferably 2.1 or more and 3.6 or less, and further preferably 2.2 or more and 3 or less.
  • the IOB value is calculated according to the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is OR A , the inorganic value is IN A , the organic value of monomer B is OR B , the inorganic value There is iN B, when the molar ratio of the monomer a / monomer B is M a / M B, IOB value of copolymer is calculated from the following equation.
  • the hemagglutinating agent used in the present invention includes one third component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. It may be in the form of a composition (hemagglutinating agent composition) contained above.
  • a solvent water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used.
  • the plasticizer glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used.
  • fragrance there can be used a fragrance having a green herbal-like fragrance, a plant extract, a citrus extract and the like described in JP-A-2007-244664.
  • Antibacterial and deodorant agents include cancrinite-like minerals containing metals having antibacterial properties described in JP-A-2004-244789, and polymerizability having a phenyl group described in JP-A-2007-097953. Porous polymers polymerized from monomers, quaternary ammonium salts, activated carbon, clay minerals and the like described in JP-A-2006-191966 can be used.
  • skin care agents plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in JP-A No. 2004-255164 can be used.
  • the proportion of the cationic polymer in the hemagglutinating agent composition is preferably 20% by mass or more, more preferably 40% by mass or more, and further preferably 50% by mass or more. Further, it is preferably 99% by mass or less, more preferably 80% by mass or less, and still more preferably 60% by mass or less.
  • the ratio of the hemagglutinating agent contained in the hemagglutinating fiber of the present invention is preferably 1% by mass or more, more preferably 5% by mass or more, from the viewpoint of expressing sufficient hemagglutination action. More preferably, it is 10 mass% or more. Moreover, from a viewpoint of making it exist in the inside of a fiber, it is preferable that it is 50 mass% or less, it is still more preferable that it is 45 mass% or less, and it is still more preferable that it is 40 mass% or less.
  • the proportion of the hemagglutinating agent contained in the hemagglutinating fiber is preferably 1% by mass to 50% by mass, more preferably 5% by mass to 45% by mass, and further preferably 10% by mass to 40% by mass. More preferably, it is as follows.
  • the ratio of the hemagglutinating agent contained in the hemagglutinating fiber is measured by the following method.
  • a product such as a napkin to be measured is weakened with an adhesive using a cold spray, carefully peeled off, and divided into each member.
  • Each member is immersed in deionized water for 60 minutes to elute the hemagglutinating agent composition. Thereafter, the deionized water from which the resulting hemagglutinating agent composition has been eluted is dialyzed.
  • the dialysis treatment is a treatment for removing water-soluble low molecular weight components such as solvents, plasticizers, fragrances, antibacterial / deodorants, skin care agents, etc.
  • a dialysis tube that can remove components having a molecular weight of 2000 or less is used . After dialysis, evaporate to dryness or freeze-dry. Thereafter, 1 H-NMR, mass spectrometry (MS) or the like is used alone or in combination to identify the hemagglutinating agent. By measuring the mass of the identified hemagglutinating agent, the total amount of hemagglutinating agent can be determined. Obtaining the proportion of the hemagglutinating agent contained in the hemagglutinating fiber based on the total amount of the hemagglutinating agent thus obtained and the mass of the hemagglutinating fiber before eluting the hemagglutinating agent composition. Can do. Moreover, a differential molecular weight distribution curve can be obtained by measuring the identified hemagglutinating agent by gel permeation chromatography.
  • Penetration method (1) The dried fiber is immersed in the solution. This solution contains a solvent having affinity for both the hemagglutinating agent and the fiber, and a hemagglutinating agent dissolved in the solvent. “Affinity” means the property or tendency of a substance to easily bind to another substance. In the case of liquid and solid, the contact angle is 90 degrees or less. Is a state of being mixed and dissolved.
  • Penetration method (2) Wet the dried fiber with a solvent. This solvent has an affinity for both hemagglutinating agents and fibers.
  • the wet fiber is immersed in a solution containing a hemagglutinating agent.
  • a hemagglutinating agent include water and a mixed solvent of water and alcohol when the fiber is a hydrophilic fiber.
  • various organic solvents and supercritical carbon dioxide can be used.
  • Penetration method (3) When the raw material of the fiber is a thermoplastic resin having fiber forming ability, a hemagglutinating agent is kneaded into the molten resin, and melt spinning is performed.
  • the fibers of the hemagglutinating agent can be compared with the case where the soaking time is short.
  • the penetration rate of sucrose was improved.
  • the fiber having a high permeability improves the sustained release property of the hemagglutinating agent as compared with the fiber having a low permeability (Examples 1 and 10 described later). .
  • the hemagglutinating fiber of the present invention can be used, for example, in the form of a fiber stack formed by separately stacking the fibers, or can be used in the form of a fiber stack formed by mixing with other fibers. it can.
  • the hemagglutinating fiber of the present invention can be used alone or mixed with other fibers and used in the form of a fiber sheet containing the hemagglutinating fiber.
  • These piles and fiber sheets can be suitably used as constituent members of menstrual absorbent articles such as sanitary napkins. Below, an example of the absorbent article which has the member containing the hemagglutination fiber of this invention is demonstrated.
  • FIG. 1 shows a sanitary napkin 1.
  • the napkin 1 has a longitudinal direction X corresponding to the wearer's front-rear direction and a transverse direction Y orthogonal thereto, and is disposed on the skin facing surface side of the absorbent body 4 and capable of absorbing menstrual blood.
  • a top sheet 2 that can come into contact with the wearer's skin when worn.
  • the “skin-facing surface” is a surface of the absorbent article or a component thereof (for example, the absorbent body 4) that is directed toward the wearer's skin when the absorbent article is worn, that is, relative to the wearer's skin.
  • the side close to the skin, and the “non-skin facing surface” is directed to the side opposite to the skin side when the absorbent article is worn, that is, the side that is relatively far from the wearer's skin. It is the surface to be.
  • “at the time of wearing” here means the state in which the normal proper wearing position, that is, the correct wearing position of the absorbent article is maintained, and the absorbent article is in a state deviated from the wearing position. Is not included.
  • the napkin 1 includes an absorbent main body 10 including a top sheet 2 that forms a skin facing surface, a back sheet 3 that forms a non-skin facing surface, and an absorbent body 4 interposed between both sheets 2 and 3. .
  • the absorbent main body 10 is disposed on the abdomen side, that is, the front side of the wearer from the excretion part facing part B, which is an area disposed opposite to the wearer's liquid excretion part (such as the vaginal opening) when worn.
  • the front portion A and the rear portion C arranged on the back side of the wearer, that is, the rear side of the excretory portion facing portion B are provided in the vertical direction X.
  • the napkin 1 or the absorbent main body 10 is divided into three regions of the front part A, the excretory part facing part B, and the rear part C in order from the wearer's stomach side in the longitudinal direction X.
  • the longitudinal direction X coincides with the longitudinal direction of the napkin 1 and the absorbent main body 10
  • the lateral direction Y coincides with the width direction orthogonal to the longitudinal direction of the napkin 1 and the absorbent main body 10.
  • the top sheet 2 covers the entire skin facing surface of the absorbent body 4, and both side edges along the longitudinal direction X are substantially in the same position as both side edges along the longitudinal direction X of the absorbent body 4.
  • the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4 and further extends outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4 to be described later.
  • a side flap portion 10S is formed.
  • the back sheet 3 and the side sheet 6 are joined to each other by known joining means such as an adhesive, heat seal, ultrasonic seal, and the like at the extended portions from both side edges along the longitudinal direction X of the absorber 4.
  • the surface sheet 2 and the back surface sheet 3 are joined to each other by a known joining means at the extending portions from both ends in the longitudinal direction X of the absorber 4.
  • the top sheet 2 and the back sheet 3 may be bonded to the absorber 4 with an adhesive.
  • top sheet 2 and the back sheet 3 various kinds of materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation.
  • the back sheet 3 a liquid hardly permeable and moisture permeable resin film, a laminated sheet of the resin film and a nonwoven fabric, or the like can be used.
  • the surface sheet 2 a single layer or multilayer nonwoven fabric, a perforated film, or the like can be used.
  • the top sheet 2 can be coated with various oil agents for improving liquid permeability, for example, various surfactants.
  • the topsheet 2 When the topsheet 2 has a multilayer structure, the topsheet 2 includes a first fiber layer located on the side close to the wearer's skin and a second fiber layer located on the side far from the wearer's skin. And both fiber layers are integrated in the thickness direction by a number of joints formed in part, and a portion of the first fiber layer located between the joints is convex. It is possible to use a concavo-convex sheet that protrudes and forms the concavo-convex convex portion.
  • the convex portion of the concavo-convex sheet may have a solid structure that is entirely filled with fibers, or may have a hollow structure having a space inside.
  • the concavo-convex sheet in which the convex portion has a solid structure for example, those described in Japanese Patent Application Laid-Open Nos. 2007-182626 and 2002-187228 can be used.
  • the surface sheet 2 may be embossed.
  • embossing pattern there is no restriction
  • a so-called round emboss having a closed shape along the periphery can be formed at a position inside the periphery of the absorbent body 4.
  • a portion corresponding to the side edge of the absorbent body 4 has a shape that bulges outward in the width direction of the absorbent body 4.
  • This round embossing may be composed of an assembly of discontinuous embossing patterns within a range that can be regarded as continuous when viewed as a whole.
  • the absorbent main body 10 includes a second sheet 5.
  • the second sheet 5 is liquid permeable and is disposed between the top sheet 2 and the absorber 4.
  • the second sheet 5 is a constituent member of an absorbent article that is also called a sublayer sheet or the like in this technical field, and improves the permeability of the liquid from the top sheet 2 to the absorbent body 4, and the surface of the liquid absorbed by the absorbent body 4. It plays a role of reducing liquid return to the sheet 2.
  • the second sheet 5 covers substantially the entire skin facing surface of the absorbent body 4.
  • a hydrophilic nonwoven fabric or a hydrophilic fiber aggregate can be used as the second sheet 5.
  • nonwoven fabric examples include an air-through nonwoven fabric, a point bond nonwoven fabric, a resin bond nonwoven fabric, a spunlace nonwoven fabric, and an airlaid nonwoven fabric.
  • the basis weight of the second sheet 5 is preferably 10 g / m 2, more preferably 15 g / m 2 or more, and preferably 50 g / m 2 or less, more preferably 40 g / m 2 or less.
  • the thickness of the second sheet 5 is preferably 0.1 mm or more and 5 mm or less.
  • a pair of skin facing surfaces of the absorbent main body 10 that is, both side portions along the longitudinal direction X of the skin facing surface of the topsheet 2, so as to overlap both left and right side portions along the longitudinal direction X of the absorbent body 4 in plan view.
  • the side sheets 6 and 6 are arranged over substantially the entire length in the longitudinal direction X of the absorbent main body 10.
  • the pair of side sheets 6 and 6 are joined to the top sheet 2 by a known joining means at joining lines 61 extending in the longitudinal direction X.
  • the napkin 1 further includes a pair of wing portions 10 ⁇ / b> W and 10 ⁇ / b> W that extend outward in the lateral direction Y from both side portions along the vertical direction X of the excretory part facing portion B of the absorbent main body 10. have. That is, the napkin 1 has the absorptive main body 10 and a pair of wing parts 10W and 10W.
  • the excretion part opposing part B is a region having the wing part 10W in the longitudinal direction (X direction in the drawing) of the napkin 1 (along the longitudinal direction X of one wing part 10W). Means a region sandwiched between the base and the base along the longitudinal direction X of the other wing portion 10W.
  • the excretion part facing part B when the napkin 1 does not have a wing part traverses the napkin 1 in the lateral direction (Y direction in the figure) generated when the napkin 1 is folded into a three-fold individual form. With respect to two fold lines (not shown), it means a region surrounded by a first fold line and a second fold line as counted from the front end in the longitudinal direction X of the napkin 1.
  • the side flap portion 10 ⁇ / b> S projects greatly outward in the lateral direction Y at the excretory portion facing portion B, whereby a pair of wing portions 10 ⁇ / b> W and 10 ⁇ / b> W are provided on both left and right sides along the longitudinal direction X of the absorbent main body 10. It is extended.
  • the wing portion 10W has a substantially trapezoidal shape in which the lower base (side longer than the upper base) is located on the side of the napkin 1 in a plan view as shown in FIG.
  • the wing part adhesion part (not shown) which fixes the wing part 10W to clothes, such as shorts, is formed.
  • the wing part 10W is folded and used on the non-skin facing surface (outer surface) side of the crotch part of clothes such as shorts.
  • the wing adhesive section is covered with a release sheet (not shown) made of a film, nonwoven fabric, paper, or the like before use.
  • the absorber 4 contains a superabsorbent polymer.
  • the superabsorbent polymer contained in the absorbent body 4 is generally a particulate polymer, but may be a fibrous polymer.
  • the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape.
  • the superabsorbent polymer generally, a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof.
  • sodium salts can be preferably used.
  • the absorbent body 4 further contains hydrophilic fibers in addition to the superabsorbent polymer.
  • hydrophilic fibers contained in the absorbent body 4 include those obtained by hydrophilizing hydrophobic fibers and those that are hydrophilic per se, and these are used alone or in combination of two or more. Can be used. Particularly preferred are those which are themselves hydrophilic and have water retention. Preferred examples of the latter hydrophilic fibers include natural fibers, cellulosic regenerated fibers, and semi-synthetic fibers.
  • pulp and rayon are particularly preferable, and pulp is more preferable. In addition to wood pulp such as softwood kraft pulp and hardwood kraft pulp, pulp includes non-wood pulp such as cotton pulp and straw pulp, but is not particularly limited.
  • the embossing can be applied to the absorber 4. Embossing may be performed only on the absorbent body 4 or may be performed together on the top sheet 2 and the absorbent body 4 described above. By embossing the top sheet 2 and the absorbent body 4 together, these members are joined at the embossed portion by thermal fusion and / or pressure bonding. When the above-described round embossing is performed on the top sheet 2, the round embossing can also be performed on the absorbent body 4 and the absorbent body 4 and the top sheet 2 can be joined by round embossing. .
  • the absorbent body 4 includes an absorbent core containing hydrophilic fibers and a superabsorbent polymer.
  • the absorptive core of this embodiment consists of a mixed fiber body of a pulp fiber and a superabsorbent polymer.
  • the mixed fiber stack is manufactured by a known drum-type fiber stacking apparatus including a stacking drum having a stacking concave portion on the peripheral surface, and is sucked from the bottom surface of the stacking concave portion, The surface is supplied with pulp fibers and superabsorbent polymer as the absorbent core forming material in a scattered state, and after the absorbent core forming material is deposited in the accumulation recess, it is released from the accumulation recess. Is obtained.
  • the absorbent core of the present embodiment may be a single fiber stack of pulp fibers that does not contain a superabsorbent polymer.
  • the absorbent core may be a single layer, but may have a laminated structure including the lower absorbent core 41 and the upper absorbent core 42.
  • the absorbent body 4 having a laminated structure is overlapped with the lower absorbent core 41 disposed opposite to the excretion part of the wearer when worn, and in a plan view as shown in FIG.
  • the lower absorbent core 41 has a laminated structure including an upper absorbent core 42 having a portion 42E extending outward from at least a part of the periphery of the lower absorbent core 41.
  • the “periphery of the central absorbent sheet” means the peripheral edge of the lower absorbent core 41 in a state of being incorporated in the napkin 1.
  • the upper absorbent core 42 extends outward from the entire periphery of the lower absorbent core 41.
  • the central portion in the lateral direction Y of the excretory portion-facing portion B is a so-called middle-high portion that is thicker than the peripheral portion.
  • the middle and high portions may be formed by arranging a large amount of hydrophilic fibers and superabsorbent polymer only in a part of the single-layer absorbent core.
  • the at least upper and lower surfaces of the absorbent core are covered with a covering sheet (not shown).
  • the entire absorbent core is covered with a covering sheet.
  • the absorber 4 has a structure in which an absorbent core containing a superabsorbent polymer and / or hydrophilic fibers is covered with a covering sheet.
  • the covering sheet is liquid permeable.
  • a thin paper mainly composed of cellulose fibers, a non-woven fabric subjected to a hydrophilic treatment, or the like is used.
  • the napkin 1 includes a hemagglutinating agent because any one of the constituent members includes a hemagglutinating fiber.
  • the hemagglutinating fiber is advantageously present in the napkin 1 in such a manner as to come into contact with menstrual blood excreted by the napkin 1.
  • the hemagglutinating fiber is preferably present on the skin facing surface side of the back sheet 3 or on the skin facing surface side of the back sheet 3, and the absorbent body 4 or the skin facing surface thereof. It is more preferable that it exists in the site
  • the hemagglutinating fiber is any one member or any two of the covering sheet in the absorbent body 4, the top sheet 2, or the second sheet disposed between the covering sheet and the top sheet 2. It is preferable to be contained in the above members.
  • these members contain hemagglutinating fibers, the menstrual blood comes into contact with the hemagglutinating fibers before the menstrual blood reaches the absorbent core, which is the site containing the superabsorbent polymer. This is advantageous because it can cause aggregation of red blood cells in the menstrual blood before the menstrual blood reaches the absorbent core. Even when hemagglutinating fibers are included in the absorbent core, the agglutination effect of erythrocytes is observed.
  • hemagglutinating fibers in the cover sheet, the top sheet 2 and / or the second sheet 5 because the effect of erythrocyte aggregation is enhanced.
  • the fibers may exist throughout the sheet, or may exist only in a part of the sheet.
  • a sheet containing hemagglutinating fibers as constituent members of various absorbent articles including the sanitary napkin 1 shown in FIG. 1 are as described below.
  • the absorption rate and absorption amount of moisture by the superabsorbent polymer vary depending on the type of moisture.
  • blood absorbs slower and absorbs less than physiological saline.
  • the following facts have been found. Blood is roughly divided into liquid components such as plasma and non-liquid components such as red blood cells, and the components absorbed by the superabsorbent polymer are liquid components such as plasma. As shown in FIG.
  • the absorption performance is expressed on the basis of the absorption amount and the absorption rate.
  • the amount of absorption can be expressed as the ratio of the volume of the superabsorbent polymer 14 before absorption to the volume of the superabsorbent polymer 14 after absorption, that is, the volume swelling magnification described later.
  • the absorption rate can be expressed as the slope of the volume swell ratio of the superabsorbent polymer 14 over time.
  • the present invention further discloses the following hemagglutinating fiber and a method for producing the same.
  • a method for producing a hemagglutinating fiber comprising a step of immersing the dried fiber in a solution containing a solvent having affinity for both the hemagglutinating agent and the fiber and a hemagglutinating agent dissolved in the solvent.
  • ⁇ 2> A solvent having an affinity for both the hemagglutinating agent and the fiber, the wet fiber is wetted with the solvent,
  • a method for producing a hemagglutinating fiber comprising a step of immersing the wet fiber in a solution containing the hemagglutinating agent.
  • the solvent is water or a mixed solvent of water and alcohol
  • the solvent is various organic solvents, or the method for producing a hemagglutinating fiber according to ⁇ 1> or ⁇ 2>, which is supercritical carbon dioxide.
  • ⁇ 4> A method for producing a hemagglutinating fiber comprising a step of kneading a hemagglutinating agent in a molten state of a thermoplastic resin having fiber forming ability and performing melt spinning.
  • ⁇ 5> A hemagglutinating fiber produced by the method according to any one of ⁇ 1> to ⁇ 4>.
  • ⁇ 6> A hemagglutinating fiber in which a hemagglutinating agent is contained inside the fiber.
  • the beating degree is 100 mL or more and 780 mL or less, preferably 600 mL or less, more preferably 400 mL or less, preferably 200 mL or more, more preferably 300 mL or more, preferably 200 mL or more and 600 mL or less, more preferably 300 mL or more and 400 mL or less.
  • the natural fiber is a cellulose fiber or a rayon fiber
  • the fiber is a synthetic fiber;
  • the synthetic fibers include various polyolefin fibers such as polyethylene and polypropylene, various polyester fibers such as polyethylene terephthalate and polybutylene terephthalate, various acrylic fibers such as polyacrylic acid and polymethyl methacrylate, and polystyrene and polyvinyl chloride.
  • the hemagglutinating agent has a weight average molecular weight of 2000 to 10 million, preferably 10,000 or more, more preferably 30,000 or more, preferably 5 million or less, more preferably 3 million or less, preferably The hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 14>, which is 10,000 to 5,000,000, more preferably 30,000 to 3,000,000.
  • the relatively low molecular weight hemagglutinating agent has a weight average molecular weight of 2,000 to 150,000, preferably 10,000 or more, more preferably 30,000 or more, preferably 100,000 or less, more preferably
  • the hemagglutinating agent having a relatively high molecular weight is 150,000 to 3 million, preferably on the condition that its weight average molecular weight is higher than that of a relatively low molecular weight cationic polymer, preferably 300,000 or more, more preferably 500,000 or more, preferably 2 million or less, more preferably 1 million or less, preferably 300,000 or more and 2 million or less, more preferably 500,000 or more and 1 million or less.
  • the relatively high molecular weight hemagglutinating agent has a weight average molecular weight of 500,000 or more and 1,000,000 or less, provided that its weight average molecular weight is higher than that of a relatively low molecular weight cationic polymer.
  • the difference in peak in molecular weight distribution between the relatively high molecular weight hemagglutinating agent and the relatively low molecular weight hemagglutinating agent is 300,000 to 3,000,000, preferably 500,000, more preferably The hemagglutination according to the above ⁇ 22>, which is 700,000 or more, preferably 2 million or less, more preferably 1 million or less, preferably 500,000 to 2 million, more preferably 700,000 to 1 million. Sex fibers.
  • ⁇ 24> The hemagglutination property according to ⁇ 22>, wherein the difference in peak of the molecular weight distribution between the relatively high molecular weight hemagglutinating agent and the relatively low molecular weight hemagglutinating agent is 700,000 to 1,000,000. fiber.
  • the thickness of the fiber is 0.1 ⁇ m or more and 1000 ⁇ m or less, preferably 1 ⁇ m or more, more preferably 10 ⁇ m or more, preferably 500 ⁇ m or less, more preferably 200 ⁇ m or less, preferably 1 ⁇ m or more and 500 ⁇ m or less,
  • the hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 24> which is preferably 10 ⁇ m or more and 200 ⁇ m or less.
  • ⁇ 26> The hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 24>, wherein the fiber has a thickness of 10 ⁇ m to 200 ⁇ m.
  • the ratio of the hemagglutinating agent contained in the hemagglutinating fiber is 1% by mass or more and 50% by mass or less, preferably 5% by mass or more, more preferably 10% by mass or more, and preferably 45% by mass or less. More preferably, it is 40% by mass or less, preferably 5% by mass or more and 45% by mass or less, more preferably 10% by mass or more and 40% by mass or less, according to any one of the above ⁇ 5> to ⁇ 27>.
  • Hemagglutinating fiber ⁇ 29> The hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 27>, wherein the ratio of the hemagglutinating agent contained in the hemagglutinating fiber is 10% by mass or more and 40% by mass or less.
  • the hemagglutinating agent is an acrylamide copolymer or polylysine, Is a triblock copolymer of polypropylene oxide or polyethylene oxide, Cationized cellulose, hydroxypropyltrimonium chloride starch, Or the hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 29>, which is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.
  • the hemagglutinating agent is a water-soluble cationic polymer;
  • the water-soluble cationic polymer has a structure having a main chain and a side chain bonded thereto, and has a molecular weight of 2000 or more, A quaternary ammonium salt homopolymer having a repeating unit represented by the following formula 1, or A quaternary ammonium salt copolymer having a repeating unit represented by the following formula 1 and a repeating unit represented by the following formula 2: Any one of ⁇ 5> to ⁇ 30>, wherein the main chain and the side chain of the water-soluble cationic polymer are bonded at one point, and the side chain has a quaternary ammonium moiety.
  • the hemagglutinating fiber according to 1.
  • the hemagglutinating agent preferably has a streaming potential of 1500 ⁇ eq / L or more, more preferably 2000 ⁇ eq / L or more, still more preferably 3000 ⁇ eq / L or more, and even more preferably 4000 ⁇ eq / L or more.
  • it is 13000 ⁇ eq / L or less, more preferably 8000 ⁇ eq / L or less, and even more preferably 6000 ⁇ eq / L or less, a quaternary ammonium salt homopolymer or a quaternary ammonium salt copolymer.
  • the hemagglutinating agent preferably has an IOB value of 0.6 or more, more preferably 1.8 or more, still more preferably 2.1 or more, and even more preferably 2.2 or more. Preferably, it is 4.6 or less, more preferably 3.6 or less, and even more preferably 3 or less, and any one of the above ⁇ 5> to ⁇ 32> comprising the cationic polymer Hemagglutinating fiber.
  • ⁇ 34> A cationic polymer-containing fiber in which a cationic polymer is contained inside the fiber.
  • the beating degree is 100 mL or more and 780 mL or less, preferably 600 mL or less, more preferably 400 mL or less, preferably 200 mL or more, more preferably 300 mL or more, preferably 200 mL or more and 600 mL or less, more preferably 300 mL or more and 400 mL or less.
  • the cationic polymer has a weight average molecular weight of 2000 to 10 million, preferably 10,000 or more, more preferably 30,000 or more, preferably 5 million or less, more preferably 3 million or less, preferably 1
  • ⁇ 39> The cationic polymer-containing fiber according to any one of ⁇ 34> to ⁇ 37>, wherein the cationic polymer has a weight average molecular weight of 30,000 to 3,000,000.
  • ⁇ 40> The cationic polymer-containing fiber according to any one of ⁇ 34> to ⁇ 39>, wherein the fiber is a cellulose fiber, a rayon fiber, or a fiber made of a thermoplastic resin having fiber forming ability.
  • ⁇ 41> The cationic polymer-containing fiber according to any one of ⁇ 34> to ⁇ 39>, wherein the fiber is a cellulose fiber.
  • the cationic polymer is an acrylamide copolymer or polylysine, Is a triblock copolymer of polypropylene oxide or polyethylene oxide, Cationized cellulose, hydroxypropyltrimonium chloride starch,
  • the cationic polymer-containing fiber according to any one of ⁇ 34> to ⁇ 41> which is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate.
  • a fiber sheet comprising the hemagglutinating fiber according to any one of ⁇ 5> to ⁇ 33> or the cationic polymer-containing fiber according to any one of ⁇ 34> to ⁇ 42>.
  • Example 1 The hemagglutinating agent was permeated into the fiber according to the permeation method (1) described above.
  • a hemagglutinating agent composed of a quaternary ammonium salt polymer polydiallyldimethylammonium chloride (hereinafter also referred to as “pDADMAC”), which is a water-soluble quaternary ammonium salt homopolymer.
  • pDADMAC polydiallyldimethylammonium chloride
  • Unisense FPA1002L manufactured by SENKA CORPORATION. Ten thousand. was used.
  • the fiber pulp fiber having a beating degree of 550 mL shown in Table 2 was used. Deionized water was used as a solvent, and pDADMAC was dissolved in this solvent to form a solution.
  • the concentration of pDADMAC in the solution was 0.1 g / mL.
  • the pulp fiber was immersed in this solution at room temperature, and pDADMAC was infiltrated into the fiber. The immersion time was 60 minutes. After pulling up the pulp fibers from the solution, the solvent was dried to obtain hemagglutinating fibers. The ratio of pDADMAC in this hemagglutinating fiber was 31%.
  • Example 2 This example is an example in which the method of immersing the hemagglutinating agent in the fibers is different from that in Example 1.
  • the hemagglutinating agent was infiltrated into the fibers according to the infiltration method (2) described above.
  • Deionized water was used as a solvent, and the same pulp fiber as in Example 1 was immersed in this solvent at room temperature. The immersion time was 60 minutes. After lifting the pulp fiber from the solvent, it was immersed in a deionized aqueous solution containing 10% of pDADMAC at room temperature. After pulling up the pulp fibers from the solution, the solvent was dried to obtain hemagglutinating fibers.
  • the ratio of pDADMAC in this hemagglutinating fiber was 31%. Except this, it was the same as Example 1.
  • Example 3 In this example, instead of the pulp fiber used in Example 1, a pulp fiber having a beating degree of 770 mL was used. Except this, it was the same as Example 1. The ratio of pDADMAC in the obtained hemagglutinating fiber was 31%.
  • Example 4 In this example, instead of the pulp fiber used in Example 1, a pulp fiber having a beating degree of 350 mL was used. Except this, it was the same as Example 1. The ratio of pDADMAC in the obtained hemagglutinating fiber was 31%.
  • Example 5 polymethacrylic acid dimethylaminoethyl diethyl sulfate (hereinafter also referred to as “pMOEDES”, weight average molecular weight 790,000) was used instead of pDADMAC used in Example 1. Except this, it was the same as Example 1. The ratio of pMOEDES in the obtained hemagglutinating fiber was 31%.
  • Example 6 In this example, pMOEDES (weight average molecular weight 160,000) was used instead of pDADMAC used in Example 1. Except this, it was the same as Example 1. The ratio of pMOEDES in the obtained hemagglutinating fiber was 31%.
  • Example 7 in place of pDADMAC used in Example 1, a poly [dimethylaminoethylethyldiethyl sulfate sulfate / methyl methacrylate] copolymer (hereinafter also referred to as “pMOEDES / MMA”, weight average molecular weight 350,000). It is an example using. Except this, it was the same as Example 1. The ratio of pMOEDES / MMA in the obtained hemagglutinating fiber was 31%.
  • Example 8 In this example, instead of pDADMAC used in Example 1, pMOEDES (weight average molecular weight 790,000) and pMOEDES (weight average molecular weight 56,000) were used. As a result of using two types of hemagglutinating agents, two peaks were observed in the molecular weight distribution. Except this, it was the same as Example 1. The ratio of the hemagglutinating agent in the obtained hemagglutinating fiber was 31%.
  • Example 9 In this example, instead of pDADMAC used in Example 1, pMOEDES (weight average molecular weight 790,000) and pMOEDES (weight average molecular weight 300,000) were used. As a result of using two types of hemagglutinating agents, two peaks were observed in the molecular weight distribution. Except this, it was the same as Example 1. The ratio of the hemagglutinating agent in the obtained hemagglutinating fiber was 31%.
  • Example 10 In this example, the immersion time of the pulp fiber used in Example 1 in the solution was 12 hours. Except this, it was the same as Example 1. The ratio of pDADMAC in this hemagglutinating fiber was 31%.
  • Example 1 the pulp fiber used in Example 1 was subjected to water repellent treatment.
  • the water repellent treatment prevented the hemagglutinating agent from penetrating into the pulp fiber. Except this, it was the same as Example 1.
  • the ratio of the hemagglutinating agent in the obtained fiber was 31%.
  • Example 2 In this reference example, instead of the pulp fiber used in Example 1, a PET / PE core-sheath synthetic fiber having a fineness of 3.3 dtex is used. This fiber prevents the hemagglutinating agent from penetrating into the fiber. Except this, it was the same as Example 1. The ratio of the hemagglutinating agent in the obtained fiber was 31%.
  • the permeability of the hemagglutinating agent was measured by the above-mentioned method.
  • the volume swelling magnification of the superabsorbent polymer was measured by the following method.
  • the volume swelling ratio is a scale representing the amount of absorption of the superabsorbent polymer.
  • the change with time of the volume swelling ratio is a measure of the sustained release property of the hemagglutinating agent from the fiber, and the greater the number of times the volume swelling magnification shows a larger value, the better the sustained release property of the hemagglutinating agent. Means that. The results are shown in Table 3 below.
  • One superabsorbent polymer having a diameter of about 400 ⁇ m was placed on a glass slide, and 3 drops of each collected simulated blood was dropped onto the superabsorbent polymer with a Pasteur pipette. The simulated blood was absorbed and swollen. As the superabsorbent polymer, cross-linked sodium polyacrylate was used. After the simulated blood was dripped, the superabsorbent polymer was sealed using a small screw cap to prevent moisture transpiration. After 10 minutes, the lid was removed, and an excess amount of simulated blood was absorbed and removed using absorbent paper. Subsequently, the diameter of the superabsorbent polymer was measured with an optical microscope. When the diameter of the superabsorbent polymer before swelling is R1 ( ⁇ m) and the diameter after swelling is R2 ( ⁇ m), the volume swelling ratio is defined by (R2 / R1) 3 .
  • the hemagglutinating fiber obtained in each example is difficult to decrease over time in the volume swelling ratio of the superabsorbent polymer, whereas in the fiber of the reference example, It can be seen that the volume swelling ratio of the superabsorbent polymer decreases rapidly with time. For this reason, the hemagglutinating fibers obtained in each Example have sustained menstrual blood treatment effects even after repeatedly contacting with simulated blood.
  • the hemagglutinating fiber obtained in Example 10 was obtained by increasing the immersion time of the pDADMAC solution in the pulp fiber as compared with Example 1.
  • the penetration rate of the hemagglutinating agent into the fibers was improved, and the sustained release property of the hemagglutinating agent was also excellent.
  • a hemagglutinating fiber that maintains the agglutination action of red blood cells even when repeatedly contacted with menstrual blood.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Textile Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

La présente invention concerne une fibre d'agglutination de cellules sanguines qui contient un agent d'agglutination de cellules sanguines à l'intérieur de cette dernière. Il est préférable que : la vitesse de pénétration de l'agent d'agglutination de cellules sanguines dans la fibre soit d'au moins 2 ; la fibre, de préférence l'indice d'égouttage de cette dernière étant inférieur ou égal à 780 ml, est une fibre de cellulose ; l'agent d'agglutination de cellules sanguines est composé d'un polymère cationique ; la masse moléculaire moyenne en poids du polymère cationique est d'au moins 10 000 ; et au moins deux sortes de polymères cationiques ayant des masses moléculaires moyennes en poids différentes sont incluses.
PCT/JP2017/015969 2016-06-03 2017-04-21 Fibre d'agglutination de cellules sanguines WO2017208665A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780033387.2A CN109196160A (zh) 2016-06-03 2017-04-21 血细胞凝集性纤维

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016111624 2016-06-03
JP2016-111624 2016-06-03

Publications (1)

Publication Number Publication Date
WO2017208665A1 true WO2017208665A1 (fr) 2017-12-07

Family

ID=60265787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/015969 WO2017208665A1 (fr) 2016-06-03 2017-04-21 Fibre d'agglutination de cellules sanguines

Country Status (4)

Country Link
JP (1) JP6228705B1 (fr)
CN (1) CN109196160A (fr)
TW (1) TWI673072B (fr)
WO (1) WO2017208665A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4980311A (fr) * 1972-12-04 1974-08-02
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2003306404A (ja) * 2002-01-29 2003-10-28 Clariant Gmbh 殺生物作用を有するポリマー、それの製造法及び使用法
JP2009506056A (ja) * 2005-08-22 2009-02-12 クイック−メッド テクノロジーズ、インク． 基質の表面に抗菌カチオン性多価電解質を付着する方法
JP2010220903A (ja) * 2009-03-25 2010-10-07 Kao Corp 吸収体及びその製造方法並びに吸収性物品
JP2011520531A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー 吸収性コア
WO2016093233A1 (fr) * 2014-12-09 2016-06-16 花王株式会社 Produit sanitaire et agent de traitement de produit sanitaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100220927B1 (ko) * 1995-12-26 1999-09-15 마모루 우메가에 백혈구 제거 필터재
TW200700095A (en) * 2005-02-01 2007-01-01 Basf Ag Polyamine-coated superabsorbent polymers
US20100063469A1 (en) * 2006-08-31 2010-03-11 Basf Se Polyamine-Coated Superabsorbent Polymers
WO2013072408A1 (fr) * 2011-11-15 2013-05-23 Swetree Technologies Ab Fibres cellulosiques à surface fonctionnalisée, procédé de fabrication associé et application associée

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4980311A (fr) * 1972-12-04 1974-08-02
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2003306404A (ja) * 2002-01-29 2003-10-28 Clariant Gmbh 殺生物作用を有するポリマー、それの製造法及び使用法
JP2009506056A (ja) * 2005-08-22 2009-02-12 クイック−メッド テクノロジーズ、インク． 基質の表面に抗菌カチオン性多価電解質を付着する方法
JP2011520531A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー 吸収性コア
JP2010220903A (ja) * 2009-03-25 2010-10-07 Kao Corp 吸収体及びその製造方法並びに吸収性物品
WO2016093233A1 (fr) * 2014-12-09 2016-06-16 花王株式会社 Produit sanitaire et agent de traitement de produit sanitaire

Also Published As

Publication number Publication date
JP2017217456A (ja) 2017-12-14
TWI673072B (zh) 2019-10-01
TW201742638A (zh) 2017-12-16
CN109196160A (zh) 2019-01-11
JP6228705B1 (ja) 2017-11-08

Similar Documents

Publication Publication Date Title
JP6080236B2 (ja) 生理用品及び生理用品用処理剤
WO2017209071A1 (fr) Article absorbant
JP2017217071A (ja) 生理用吸収性物品
JP6279014B2 (ja) 吸収性物品
JP6259540B2 (ja) 生理用吸収性物品
CN108778208B (zh) 吸收性物品
JP2018007705A (ja) 生理用吸収性物品
JP6228629B1 (ja) 吸収性物品
JP6279015B2 (ja) 吸収性物品
JP2017217069A (ja) 生理用吸収性物品
JP2017217078A (ja) 吸収性物品
JP6228705B1 (ja) 血球凝集性繊維
WO2017209076A1 (fr) Article absorbant hygiénique
JP6887878B2 (ja) 吸収性物品
JP6762142B2 (ja) 吸収性物品
WO2017209069A1 (fr) Article absorbant
WO2017110716A1 (fr) Article absorbant
JP6228630B1 (ja) 血球凝集性繊維
JP6802078B2 (ja) 吸収性物品
JP6220947B1 (ja) 生理用品
JP6757601B2 (ja) 生理用吸収性物品
TW201801696A (zh) 吸收性物品
WO2017209072A1 (fr) Article absorbant
WO2017110717A1 (fr) Article absorbant
JP2017217070A (ja) 生理用吸収性物品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17806225

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17806225

Country of ref document: EP

Kind code of ref document: A1